Since May 22, every LENS position has been tied to the AI infrastructure build. That concentration was deliberate when the narrative gap was widest. But the AI trade is now crowded enough that crowding itself is a risk. We strongly believe that AI is crowded, exhaustion risk is rising, and capital tends to miss under-owned names when attention collapses into one dominant theme.
LENS is not abandoning the AI thesis. We are expanding the map. Two additions today. One enters the portfolio. One enters the Watch List with a defined trigger.
Continue Reading With Our 7-Day Free Trial
PODD Enters the Portfolio Today
| # | Ticker | Company | Tier | Status | Alloc % | Entry Date | Entry $ | Current $ | Return % | 12M Target | Hard Stop $ | Thesis Break Condition | Next Catalyst |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DELL | Dell Technologies | CORE | HOLD | 8% | 22-May-26 | $291.00 | $586.06 | +101.4% | $540.00 | $218 | Q3 AI server rev below $14B OR FY2027 guide cut | +2.10% vs Oct6 close. +101.4% entry, MILESTONE: more than doubled from the entry price. |
| 2 | AVGO | Broadcom Inc. | CORE | BUY | 7% | 05-Jun-26 | $385.73 | $361.54 | -6.3% | $575.00 | $289 | Q3 AI bookings below $20B OR hyperscaler reduces XPU commitment | -3.80% vs Oct6 close, giving back the prior rally. -6.3% entry. |
| 3 | GEV | GE Vernova Inc. | CORE | BUY | 4% | 14-Jul-26 | $1,042.60 | $1,004.73 | -3.6% | $1,400.00 | $730 | Multi-quarter decline in data center/AI power orders OR hyperscaler capex reversal | -2.38% vs Oct6 close. -3.6% entry. |
| 4 | CME | CME Group | CORE | BUY | 4% | 22-Jul-26 | $249.24 | $280.56 | +12.6% | $300.00 | $200 | Sustained ADV decline OR Kalshi displaces institutional rate-hedging | +3.84% vs Oct6 close, best mover in the portfolio. +12.6% entry, new portfolio high for the position. |
| 5 | MU | Micron Technology | BASE | BUY | 5% | 05-Jun-26 | $863.57 | $1,029.00 | +19.2% | $1,500.00 | $605 | HBM pricing collapse OR Samsung closes HBM quality gap | -1.58% vs Oct6 close, extending its slide. +19.2% entry. |
| 6 | NOW | ServiceNow Inc. | BASE | BUY | 4% | 05-Jun-26 | $113.39 | $140.86 | +24.2% | $170.00 | $79 | Q2 net new ARR fails to accelerate | +2.09% vs Oct6 close. +24.2% entry. |
| 7 | GOOGL | Alphabet Inc. | BASE | BUY | 4% | 05-Jun-26 | $368.00 | $351.66 | -4.4% | $470.00 | $258 | Cloud backlog conversion below 40% | +1.14% vs Oct6 close. -4.4% entry, narrowest gap since mid-September. |
| 8 | FSLR | First Solar Inc | BASE | BUY | 4% | 11-Aug-26 | $240.91 | $177.82 | -26.2% | $310.00 | $169 | ASPs below $0.30/watt 2 consecutive quarters OR backlog below 35GW w/ weakening domestic demand | ⚠ -1.10% vs Oct6 close. -26.2% entry. Stop $169 NOT hit; buffer narrowed to 5.0% from 6.0% (low was 3.2% on Oct2). Still the closest position to its stop. |
| 9 | MRVL | Marvell Technology | SPEC | BUY | 3% | 05-Jun-26 | $238.49 | $275.28 | +15.4% | $400.00 | $155 | Scale-up optics below $200M OR FY2028 guide cut | -4.09% vs Oct6 close, largest decline in the portfolio. +15.4% entry. |
| 10 | ARES | Ares Management | SPEC | BUY | 3% | 22-Jul-26 | $119.57 | $117.22 | -2.0% | $160.00 | $92 | AUM growth reversal OR private credit market dislocation | -0.44% vs Oct6 close. -2.0% entry. |
| 11 | PODD | Insulet Corp | SPEC | BUY | 2% | 29-Jun-26 | $157.74 | $135.28 | -14.2% | $200.00 | $93 | Revenue growth falls below 10% OR Type 1 patient churn from GLP-1 | +0.41% vs Oct6 close. -14.2% entry. Thesis intact. |
| — | CASH | Undeployed Capital | — | — | 52% | — | — | — | — | — | — | — | — |
PODD enters the portfolio today. The entire diabetes device sector has been punished because Wall Street is still treating two completely different diseases as if they are the same trade.
The Market Is Misreading GLP-1 Risk
The narrative being sold is simple: GLP-1 drugs such as Ozempic, Wegovy and Zepbound reduce appetite, improve metabolic control, and therefore pressure diabetes device demand. That is true in parts of obesity and Type 2 diabetes. It is not true in Type 1 diabetes. Type 1 diabetes is an autoimmune condition. The pancreas does not produce insulin. Weight loss does not solve that. Appetite suppression does not solve that. Improved insulin sensitivity does not solve that. A GLP-1 drug does not reverse autoimmune beta-cell destruction.
Insulet Serves Insulin-Dependent Patients, Not Obesity Demand
That distinction matters because Insulet is not a generic obesity-adjacent device company. Insulet makes Omnipod, a tubeless insulin pump worn on the body, with Omnipod 5 delivering automated insulin through an automated insulin delivery system. Its historical base is anchored in insulin-requiring patients, led by Type 1, and its newer Type 2 opportunity is also insulin-intensive, not cosmetic weight loss. Management said at William Blair that Omnipod 5 is the number one automated insulin delivery system in new customer starts in the U.S. and EU, serving more than 600,000 customers across 25 markets.
The Numbers Still Support the Growth Thesis
The company’s own numbers do not look like a business being displaced. In Q1 2026, Insulet grew total revenue 30% constant currency, with U.S. Omnipod revenue up 28% and international Omnipod revenue up 45%. Management also raised full-year total company revenue growth guidance to 21% to 23%. Global customer base grew nearly 25% year over year, and the business remains structurally recurring because pods are consumables, not one-time hardware sales.
The market has still compressed PODD alongside companies where the GLP-1 debate is more complicated, including glucose monitoring and legacy pump players. That is the gap. Insulet is being priced as if GLP-1s reduce the need for insulin delivery in patients who biologically require insulin. That is not a valuation debate. That is a category error.
Why We Are Acting Now
The timing also improved. Insulet just launched its enhanced Omnipod 5 algorithm in the U.S. and expanded compatibility with Abbott’s FreeStyle Libre 3 Plus sensor. The company says that sensor integration opens Omnipod 5 to roughly 450,000 people with diabetes already using Libre 3 Plus. Management also highlighted Omnipod 6 in 2027 and a fully closed-loop Type 2 system targeted for 2028, with ADA data showing the company is moving toward lower user burden and more automation.
The external validation came independently. Citrini’s June letter, one of the most widely read thematic strategy letters in the market, specifically named the life sciences recovery as one of five trades the AI crowding cycle has left behind. PODD fits that framing precisely. A stock being priced on the wrong disease, in a sector that has been structurally under-owned because analyst attention has been entirely consumed by semiconductors, with a product cycle accelerating underneath the misvaluation.
PODD Entry Parameters
The entry parameters are specific. Ticker: PODD. Tier: SPEC. Allocation: 3.0%. Entry price reference: about $158. Twelve-month fair value target: $230, which assumes the market separates insulin-delivery necessity from GLP-1 obesity exposure and restores a premium growth multiple to a company still guiding above 20% revenue growth. The hard stop is not ordinary price action. The thesis breaks if Insulet reports real Type 1 patient churn attributable to GLP-1 adoption or if utilization deteriorates in a way management cannot explain through access, pricing, or product transition. The next catalysts are Q3 earnings, Omnipod 5 rollout updates, international expansion, and any FDA-related developments around the product roadmap.
CME Moves to the Watch List
| Ticker | Company | Sector | Date Added | Why Watching | Trigger To Add |
|---|---|---|---|---|---|
| RDDT | Reddit Inc | Communication Services | 01-Sep-26 | Estimate Revision + Narrative Correction double-hit. Q2 revenue +61% YoY (8th straight qtr >60%), EPS beat ~27%, opcash >$1B LTM, capex near-zero. Stock fell 20%+ on 'choppy search referrals' despite raised guidance. | Still tracking above the low-$140s trigger as of last check — NOT YET TRIGGERED. Verify current price given this week's market volatility. Oct29 Q3 earnings confirmation remains the primary trigger. SPEC 2%. |
| EXPE | Expedia Group Inc | Consumer Cyclical | 14-Jul-26 | Estimate Revision screener. OTA vs AI narrative gap. | Article + sector check. SPEC 1-2%. |
| ANET | Arista Networks | Technology | 04-Jun-26 | 80%+ share AI Ethernet. Joined index rebalancing Sep21. | Sustained close below $160. SPEC 1-2%. |
| NVDA | NVIDIA Corp | Technology | 23-Jun-26 | CUDA moat structural. | Close at or below $183 → SPEC 1-2%. |
| LITE | Lumentum Holdings | Technology | 09-Jun-26 | Optical AI networking. | Close at or below $737 → SPEC 1-2%. |
| SNOW | Snowflake | Technology | 29-May-26 | NRR 126%. | 15-20% pullback → $190-205. SPEC 1-2%. |
| HSY | Hershey Company | Consumer Defensive | 29-Jun-26 | Cocoa + GLP-1 fear overstated. Defensive. | Pullback to $165-170. Target $210-220. |
| LRCX (PASS) | Lam Research Corp | Technology | 23-Sep-26 evaluated, declined | Genuine AI capex tie-in but crowded, fully-recognized story. Consensus already Strong Buy, trades 47-60x earnings. | Only reconsider on a genuine dislocation, same bar as VRT. |
| LLY (PASS) | Eli Lilly and Co | Healthcare | 23-Sep-26 evaluated, declined | No coherent AI narrative. Direct conflict with PODD thesis, which argues GLP-1 fear is overstated. | Not a fit for the narrative-gap framework regardless of price. |
| P / "Everpoint" (UNVERIFIED) | Unconfirmed | Unconfirmed | 23-Sep-26 flagged | Could not verify this company exists as described. Not added pending verification. | Verify ticker/company directly in the screener tool. |
CME goes on the Watch List. The world’s dominant derivatives exchange just posted record trading volumes. The stock is near a 52-week low. One of those things will correct.
The Perpetual Futures Selloff Looks Overdone
The damage is coming from the CFTC’s approval of perpetual Bitcoin futures in the U.S. market and CME’s lawsuit challenging that decision. CME argues the approval violates the legal framework for futures because perpetuals have no expiration and should be treated differently. TD Cowen then cut its price target, and CME stock fell sharply, closing at $221 on June 26, roughly 33% below its $329.16 52-week high.
The market is acting as if retail crypto derivatives competition can impair CME’s core franchise. We do not see that in the data.
CME’s Core Business Is Still Accelerating
CME reported May 2026 average daily volume of 33.2 million contracts, a new monthly record and up 15% year over year. Interest rate ADV rose 16%, 10-Year Treasury Note futures ADV rose 30%, and Ultra 10-Year Treasury Note futures ADV rose 27%.
That is the real business. Every bank, pension fund, insurer, macro fund and corporate hedger managing rate risk still needs deep liquidity, clearing, and institutional-grade risk management. Kalshi may matter for retail crypto. It does not replace Treasury futures liquidity. CME’s own CEO made that distinction clearly at Piper Sandler, emphasizing that CME is fundamentally an institutional exchange, with perpetuals structurally ill-suited for institutional hedging.
Why We Are Waiting for Q2 Earnings
CME stays on the Watch List rather than entering today because Q2 earnings are close. The company reports before market open on July 22, 2026. We do not need to front-run that event. CME’s current price is about $221, and with a low-beta profile, this is not a name that requires urgency.
CME Watch List Parameters
The trigger is specific: a sustained close below $230 after Q2 earnings confirm the volume trajectory. If that happens, CME becomes a CORE candidate with a target allocation of 4.0%. Hard stop condition: three consecutive quarters of ADV growth below 5%. Thesis break: Kalshi or another perp platform demonstrates meaningful institutional derivatives share capture, not retail crypto volume, which is irrelevant to the core thesis.
The Map Got Bigger Today
The LENS thesis has always been simple: find the places where the dominant market narrative is provably wrong, and wait for the gap to close. For the first three months of the Index, every gap we found was in AI infrastructure. PODD and CME are the first two names where the same analytical process leads somewhere else. One company treats a disease GLP-1 cannot touch. One company earns record fees from the exact volatility that is supposedly destroying it. Same methodology. Different sector. The map got bigger today.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
